JAGX
Jaguar Health, Inc.
stockNASDAQ
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar's non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.02 | 2026-09-28 | -19.93% | 6.587 |
| 1M | 8.95 | 2026-09-04 | -46.16% | 8.894 |
| 3M | 42.15 | 2026-07-06 | -88.56% | 3.132 |
| 6M | 215.30 | 2026-04-06 | -97.76% | 0.923 |
| 1Y | 1,045.23 | 2025-10-06 | -99.54% | 2.721 |
| 2Y | 15,272.73 | 2024-10-04 | -99.97% | — |
| 5Y | 111,144,881.25 | 2021-10-05 | -100.00% | 1.558 |
Jaguar Health, Inc. (NASDAQ:JAGX) stock price today is $4.82, and today's volume is 12,864,315. JAGX is up 31.694% today. The 30 day average volume is 2.58M. JAGX market cap is $2.51M with 520,088 shares outstanding.